Current Landscape of Long-Acting ART for Treatment and Prevention of HIV

View these slides for an expert overview of available long-acting antiretroviral options for HIV treatment and pre-exposure prophylaxis, including data on safety, efficacy, and durability.
Babafemi Taiwo, MBBS
Program Director
Darrell H. S. Tan, MD, FRCPC, PhD
Format: Microsoft PowerPoint (.ppt)
File Size: 247 KB
Released: June 14, 2022

Acknowledgements

Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by an educational grant from
ViiV Healthcare

Related Content

HIV self-testing and 6-month PrEP dispensing simplified PrEP delivery with no reduction in HIV testing or PrEP adherence, reported by Clinical Care Options (CCO) from AIDS 2022

Released: August 5, 2022

Efficacy of doxycycline PEP for prevention of STIs in MSM and TGW in the DoxyPEP study, reported by Clinical Care Options (CCO) from AIDS 2022

Released: August 4, 2022

HPTN 084 updated safety and efficacy data on long-acting cabotegravir for HIV PrEP in cisgender women, reported by Clinical Care Options (CCO) from AIDS 2022

Released: August 3, 2022

Opciones de cuidado clínico (CCO) presenta a la Dra. Alicia Piñeirúa que explica los principales factores que hay que tener en cuenta a la hora de optimizar el tratamiento antirretroviral en el marco de la supresión viral en pacientes que viven con el VIH y la osteopenia

person default Alicia Piñeirúa Menéndez, MD, MPH Released: August 2, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings